Market Overview

Protalix Says Reviewing Partnering, Other Alternatives

Related PLX
Protalix Reports Phase I Clinical Study Results for PRX-106 Showed Favorable Safety, Tolerability Profile Activity
Protalix BioTherapeutics Announces AIR DNase(TM) Data Presented at the 38th European Cystic Fibrosis Conference

Protalix BioTherapeutics, Inc. (NYSE: PLX) confirms, in response to inquiries received this morning and a report appearing in the Israeli press, that the company has engaged Citigroup to assist it in reviewing a broad array of product partnering, technology sharing and other strategic alternatives. There is no assurance that Protalix will undertake any such strategic alternative.

Protalix will not comment further on this initiative unless future events would make doing so appropriate.

Posted-In: News


Related Articles (PLX)

View Comments and Join the Discussion!

Get Benzinga's Newsletters